C

Edaravone (Radicava) received U.S. FDA approval in 2017 as the newest disease-modifying therapy for amyotrophic lateral sclerosis, whereas the other listed agents have not been approved for ALS treatment [Bhandari 2018, PMID 29998226; Watanabe 2018, PMID 29371752].